In summary, a series of 2-arylbenzofuran derivatives have been designed, synthesised and evaluated as multi-target anti-AD drugs, which have ChE inhibitory activity and BACE1 inhibitory activity. This evidence concerns the gene BACE1 and Alzheimer disease.